Transforming growth factor-beta1 and IL-13 response to allergen predict steroid needs in asthmatic children

Pulm Pharmacol Ther. 2013 Apr;26(2):290-5. doi: 10.1016/j.pupt.2012.12.008. Epub 2012 Dec 29.

Abstract

Background: The remission of asthma, which is induced during specific immunotherapy (SIT) or appears spontaneously in children is not completely understood and predictors of this phenomenon are still undefined.

Objective: To assess CD4(+)CD25(+)Foxp3(+) Treg cells and cytokine/proliferation response to allergen-specific stimulation of PBMC as predictors of steroid sparing effect of SIT and steroid dosage needs without SIT during 5 years of follow-up in asthmatic children.

Methods: This is a 5-year long study of 32 asthmatic children, sensitive only to house dust mite (HDM). Eighteen children who had completed 5 years of HDM SIT - SIT group, and 14 children without SIT as a control group were studied. All patients had baseline clinical/immunological assessment; before and after observation the minimum effective ICS dose was defined and lung function was measured.

Results: In children from SIT group minimum effective ICS dose was reduced more than in children from control group (median reduction 65% vs. 0%; p<0.001). Among patients in control group asthma severity was reduced after 5 years of observation in those who had at baseline higher TGF-beta1 and lower IL-13 answer to allergen stimulation of PBMC. Better response to 5 years immunotherapy was observed in those who had at baseline higher TGF-beta1 and lower proliferation answer to allergen stimulation of PBMC.

Conclusion: Similar processes may decide on both, SIT-induced and spontaneously appearing, reduction in asthma severity. Immunotherapy was much more effective than pharmacotherapy in our study. IL-13 overproduction may impede reduction of disease severity in asthmatic children independently from TGF-beta pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Asthma / immunology
  • Asthma / therapy*
  • Child
  • Desensitization, Immunologic*
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Interleukin-13 / blood*
  • Male
  • Pyroglyphidae / immunology*
  • Transforming Growth Factor beta1 / blood*

Substances

  • Glucocorticoids
  • Interleukin-13
  • Transforming Growth Factor beta1